A viral envelope is the outermost layer of many types of viruses. It protects the genetic material in their life cycle when traveling between host cells. Not all viruses have envelopes. A viral envelope protein or E protein is a protein in the envelope, which may be acquired by the capsid from an infected host cell.
Host cell infection process Numerous human pathogenic viruses in circulation are encased in lipid bilayers, and they infect their target cells by causing the viral envelope and cell membrane to fuse. Although there are effective vaccines against some of these viruses, there is no preventative or curative medicine for the majority of them. In most cases, the known vaccines operate by inducing antibodies that prevent the pathogen from entering cells. This happens in the case of enveloped viruses when the antibodies bind to the viral envelope proteins. The membrane fusion event that triggers viral entrance is caused by the viral membrane fusion protein. Many enveloped viruses only have one protein visible on the surface of the particle, which is required for both mediating adhesion to the cell surface and for the subsequent membrane fusion process. To create potential drugs and protective vaccines for human pathogenic enveloped viruses for which there is currently no vaccine, it is essential to comprehend how the fusion step works and how antibodies interact with viral envelope proteins, particularly with the fusion protein, and how antibodies neutralize viruses. Enveloped viruses enter cells by joining a cellular membrane to their lipid bilayer membrane. Priming by proteolytic processing, either of the fusion protein or of a companion protein, is necessary for the majority of viral fusion proteins. The priming stage then gets the fusion protein ready for triggering by the processes that go along with attachment and uptake, which frequently happens during transport of the fusion protein to the cell surface but may also happen extracellularly. So far, structural studies have revealed two kinds of viral fusion proteins. These proteins are believed to catalyze the same mechanism in both situations, resulting in the fusing of two bilayers. In other words, these proteins operate as enzymes, which while having various structural variations catalyze the same chemical reaction.
Composition The envelopes are typically derived from portions of the host cell membranes (phospholipids and proteins), but include some viral glycoproteins. One of the main parts of human pathogenic viruses is glycoprotein. They have been shown to play significant roles in immunity and infection. Viral glycoproteins, a new class of cellular inhibitory proteins has been discovered. These include the E3 ubiquitin ligases of the membrane-associated RING-CH (MARCH) family, which among other things, inhibits the expression of cell surface proteins implicated in adaptive immunity. Being made up mostly of host membrane, the viral envelope can also have the proteins associated with the host cell within their membrane after budding. Many enveloped viruses mature by budding at the plasma membrane, which allows them to be discharged from infected cells. During this procedure, viral transmembrane proteins, also known as spike proteins, are integrated into membrane vesicles containing components of the viral core (capsid). For a very long time, it was thought that the spike proteins, which are necessary for infectivity, were directly incorporated into the viral core through their cytoplasmic domains. Recent research suggests that while such direct interactions may be what causes the budding of alphaviruses, this may not be the case for retroviruses and negative strand RNA viruses. These viruses can form bud particles even in the absence of spike proteins by relying only on viral core components. The spike proteins can occasionally be produced as virus-like particles without the viral core. Therefore, optimal budding and release may be dependent on a coordinated "push-and-pull" action between core and spike, where oligomerization of both components is essential.
… excerpt ends here. Continue reading the full article.
